MTERF2

Across TCGA pan-cancer cohorts, MTERF2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MTERF2 data layer compared with 27 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MTERF2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MTERF2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC and GBM are the cancer types where MTERF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	1.000	0.364	.001	14	view →
GBM	DFS	Quartile	All	0.321	1.000	.024	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

MTERF2–CCRCC (DFS)

Open the CCRCC breakdown →